{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:13:00Z","timestamp":1783563180429,"version":"3.55.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA23766"],"award-info":[{"award-number":["P01 CA23766"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We sought to describe the clinical experience of voriconazole as primary antifungal prophylaxis (AFP) in allogeneic hematopoietic cell transplant recipients (allo-HCTr). This was a single-center retrospective study of adult allo-HCTr (1 January 2014 to 31 December 2016) who received\u00a0\u2265two doses of voriconazole-AFP. Voriconazole-AFP was started on day\u00a0+7 post-HCT and continued at least through day\u00a0+60 post-HCT, or longer as clinically indicated. We reviewed the rate, reasons, and risk factors of voriconazole-AFP discontinuation until day-100 post-HCT. A total of 327 patients were included. Voriconazole-AFP was continued for a median of 69 days (mean: 57.9; range 1, 100): for a median of 90 days (mean\u00a0:84; range 2, 100) in 180\/327 (55%) in the standard-of-care (SOC) group and 20 days (mean\u00a0:25.6\u00a0; range 1, 89; P-value\u00a0&amp;lt;\u00a0.001) in 147\/327 (45%) patients in the early-discontinuation-group.\u00a0Early-voriconazole-AFP discontinuation was due to adverse events, drug interactions, insurance coverage, and other reasons in 101\/147 (68.7%), 27 (18.4%), 13 (8.8%), and 6 (4.1%) patients, respectively. Early-voriconazole-AFP discontinuation occurred in 73\/327 (22.3%) patients due to hepatotoxicity. Important predictors for early-voriconazole-AFP discontinuation included: graft-versus-host disease grade\u00a0\u22652 (odds ratio [OR]: 1.9, P-value: .02), alanine-aminotransferase\u00a0\u226575 IU\/ml on voriconazole-administration day-14 (OR: 5.6, P-value: .02) and total bilirubin\u00a0\u22651.3\u00a0mg\/dl on voriconazole-administration day-7 (OR: 3.0, P-value: .03). There were 13 proven\/probable invasive fungal infections by day-180 post-HCT (8\/147, 5.4%, and 5\/180, 2.8% in the early-discontinuation and SOC-groups, respectively; log-rank:0.13). By day-180 post HCT, 23\/147 (15.6%) and 14\/180 (7.8%) patients in the early-discontinuation and SOC-groups had died, respectively (log-rank:0.03). Voriconazole-AFP was discontinued in up to 45% of allo-HCTr. Hepatotoxicity during the first 2 weeks post-HCT is a significant predictor of early-voriconazole-AFP discontinuation.<\/jats:p>","DOI":"10.1093\/mmy\/myaa008","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T12:21:57Z","timestamp":1583497317000},"page":"1029-1036","source":"Crossref","is-referenced-by-count":19,"title":["Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm"],"prefix":"10.1093","volume":"58","author":[{"given":"Shuk Ying","family":"Chan","sequence":"first","affiliation":[{"name":"Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M","family":"Hughes","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Woo","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, Cornell University, New York, New York, USA"},{"name":"Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios","family":"Neofytos","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa","family":"Papanicolaou","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,14]]},"reference":[{"key":"2020111110124562000_bib1","article-title":"Prevention and treatment of Cancer-Related Infections","author":"2.2016 NGV","year":"2016","journal-title":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines)"},{"key":"2020111110124562000_bib2","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020111110124562000_bib3","first-page":"JCO1800374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020111110124562000_bib4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020111110124562000_bib5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/myc.12517","article-title":"Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether beta-cyclodextrin in haematological patients with renal impairment","volume":"59","author":"Kim","year":"2016","journal-title":"Mycoses"},{"key":"2020111110124562000_bib6","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1016\/j.ijid.2011.06.004","article-title":"Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients","volume":"15","author":"Kim","year":"2011","journal-title":"Int J Infect Dis"},{"key":"2020111110124562000_bib7","doi-asserted-by":"crossref","first-page":"e12897","DOI":"10.1111\/tid.12897","article-title":"Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Rosillo","year":"2018","journal-title":"Transplant Infect Dis"},{"key":"2020111110124562000_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/bmt.2014.286","article-title":"Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT","volume":"50","author":"Ceberio","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"2020111110124562000_bib9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2020111110124562000_bib10","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"2020111110124562000_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020111110124562000_bib12","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020111110124562000_bib13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/jpids\/piu019","article-title":"Voriconazole Therapeutic Drug Monitoring","volume":"3","author":"Hoy","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2020111110124562000_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2009.08.015","article-title":"Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Amigues","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020111110124562000_bib15","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020111110124562000_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev-med-120617-041210","article-title":"Expanding therapeutic opportunities for hematopoietic stem cell transplantation: T cell depletion as a model for the targeted allograft","volume":"70","author":"Cho","year":"2019","journal-title":"Annu Rev Med"},{"key":"2020111110124562000_bib17","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"2020111110124562000_bib18","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020111110124562000_bib19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2020111110124562000_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/58\/8\/1029\/34245488\/myaa008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/58\/8\/1029\/34245488\/myaa008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T15:13:11Z","timestamp":1605107591000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/58\/8\/1029\/5805459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,14]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,3,14]]},"published-print":{"date-parts":[[2020,11,10]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myaa008","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,3,14]]}}}